CSN5i-3, a potent, selective and orally available inhibitor of JAB1 exhibited anti-tumour activity by traping CRLs in the neddylated state, which leaded to CRLs inactivation (Schlierf et al. 2016; Xiao et al. 2019). Here, COPS5 is linked to neoplasm.